Middle East respiratory syndrome: current status and future prospects for vaccine development

Lanying Du† & Shibo Jiang
†Lindsey F. Kimball Research Institute, New York Blood Center, NY, USA

The outbreaks of Middle East respiratory syndrome (MERS) previously in Middle East and recently in South Korea have raised serious concerns worldwide, reinforcing the importance of developing effective and safe vaccines against MERS-coronavirus (MERS-CoV). A number of vaccine candidates have been developed on the basis of viral vectors, recombinant proteins, DNAs, nanoparticles, and recombinant MERS-CoV, and some of them have shown efficacy in laboratory animals. However, the paucity of financial support has made it difficult to transfer effective candidates from the preclinical stage to clinical trials. Here, we summarize currently available MERS vaccine candidates and illustrate strategies for future development, with the aim of provocating government agencies and Big Pharma to invest more funds for developing efficacious and safe MERS vaccines.

Keywords: Animal models, Middle East respiratory syndrome, Middle East respiratory syndrome coronavirus, receptor-binding domain, spike protein, vaccines

Expert Opin. Biol. Ther. (2015) 15(11):1647-1651

1. Introduction

Middle East respiratory syndrome (MERS), an emerging infectious disease first identified in June 2012, is caused by the novel MERS-coronavirus (MERS-CoV) [1]. MERS-CoV, a zoonotic virus, has bats as its natural reservoir and possibly dromedary camels as its intermediate host [2,3]. MERS-CoV infects humans, especially the elderly, people with diabetes and chronic lung diseases, and immunocompromised persons, causing severe disease with high mortality (~35%). The MERS outbreak has resulted in 1474 laboratory-confirmed cases, including 515 deaths as of August 27, 2015 [4]. There is still a possibility for MERS-CoV to spread within healthcare facilities, to which a number of cases have been linked [5,6]. Most MERS cases have been reported from Saudi Arabia, but South Korea is the second largest country with travel-associated MERS cases, which can all be traced back to Saudi Arabia. The continuous spread of MERS-CoV possibly through camel-to-human and human-to-human transmission has raised worldwide concerns, calling for immediate steps to develop effective and safe vaccines.

The genome of MERS-CoV encodes at least four unique accessory proteins, such as 3, 4a, 4b and 5, two replicase proteins (open reading frame 1a and 1b), and four major structural proteins, including spike (S), envelope (E), nucleocapsid (N), and membrane (M) proteins [7]. The accessory proteins play nonessential roles in MERS-CoV replication, but they are likely structural proteins or interferon antagonists, modulating in vivo replication efficiency and/or pathogenesis, as in the case of SARS-CoV [7-9]. The other proteins of MERS-CoV maintain different functions in virus replication. The E protein, for example, involves in virulence, and deleting the E-coding gene results in replication-competent and
propagation-defective viruses or attenuated viruses [7]. The S protein is particularly essential in mediating virus binding to cells expressing receptor dipeptidyl peptidase-4 (DPP4) through receptor-binding domain (RBD) in the S1 subunit, whereas the S2 subunit subsequently mediates virus entry via fusion of the virus and target cell membranes [10,11]. Therefore, these viral structural proteins, particularly S protein, may serve as targets for vaccine development. It is demonstrated that all circulating human MERS-CoV strains represent one single serotype and that virus isolates from other parts of the outbreaks have no differences from EMCO212, the prototype strain, in replication, interferon escape responses and serum neutralization, suggesting that vaccines developed based on the prototype virus strain unlikely affect their success against other virus strains [12,13].

2. Current status of MERS vaccines

No MERS vaccines are available for human use. Vaccines against MERS-CoV thus far developed in the laboratory can be categorized as those based on viral vectors, such as adenovirus (Ad) and Modified Vaccinia virus Ankara (MVA), or those based on recombinant viral proteins, DNAs, nanoparticles, and recombinant virus (Table 1).

Most viral vector-based MERS vaccines use the full-length S or S1 protein of MERS-CoV as the coding antigens and exhibit immunogenicity in vaccinated animals. Reports have indicated that recombinant Ad5 vectors, which encode the full-length or S1 extracellular domain, of MERS-CoV S protein induced MERS-CoV S-specific antibody responses in immunized mice, neutralizing MERS-CoV infection in vitro [14]. Ad5 or Ad41 vectors expressing full-length S protein of MERS-CoV have elicited MERS-CoV-specific antibody responses, neutralizing antibodies and T-cell responses in immunized mice [15]. Moreover, a viral vector MVA-based MERS vaccine expressing viral S protein, termed MVA-MERS-S, demonstrated efficacy against MERS-CoV infection in Ad/DPP4-transduced mice [16,17]. These studies suggest the potential of applying MERS-CoV S protein as a vaccine target. The German Center for Infection Research (DZIF) has supported the Phase I clinical trial of MVA-MERS-S vaccine candidate in humans. About USD $1.66 million was awarded to initiate this trial [18].

In addition to viral vector-based vaccines, vaccines based on the recombinant MERS-CoV S protein, in particular, RBD, have demonstrated efficacy in protecting immunized animals from MERS-CoV infection [19,20]. Several fragments, including residues 350 – 588, 358 – 588, 367 – 588, 367 – 606, 372 – 358, and 377 – 662, in the RBD of MERS-CoV S are shown to induce MERS-CoV neutralizing antibody responses in mice and/or rabbits [21,22]. Thus, similar to the RBD of severe acute respiratory syndrome coronavirus (SARS-CoV), the MERS-CoV RBD also contains a critical neutralizing domain (CND) capable of eliciting highly potent neutralizing antibodies and protective immunity against infection from MERS-CoV. Particularly, a fragment containing residues 377 – 588 of MERS-CoV RBD has been identified as a CND able to protect Ad5/hDPP4-transduced and hDPP4-transgenic mice against MERS-CoV. Notably, S377 – 588 is a very effective immunogen, as 1 µg of S377 – 588 protein could induce potent neutralizing antibody responses similar to those raised by high doses, such as 5 and 20 µg, respectively [23,24]. These reports all confirm that the RBD/CND of MERS-CoV in the S protein is an important target for the development of MERS subunit vaccines.

DNA vaccines are proven to be effective against MERS-CoV infection. An optimized DNA vaccine encoding full-length S protein of MERS-CoV was able to elicit antigen-specific neutralizing antibodies in mice, camels and rhesus macaques (non-human primates, NHPs), with six of the eight vaccinated macaques showing no radiographic evidence of infiltration after MERS-CoV challenge. Interestingly, potent antigen-specific cellular immune responses were induced in the immunized macaques, suggesting that T cell responses may also play a role in MERS-CoV protection [25]. Inovio Pharmaceuticals Inc., in collaboration with GeneOne Life Science, will perform a Phase I clinical trial for this DNA-based vaccine [26]. In addition to the DNA-only strategy, DNA-priming and protein-boosting could be an alternative vaccine approach for MERS-CoV. It is revealed that full-length S DNA priming and S1 subunit protein boosting immunization of mice and NHPs induced robust neutralizing antibody responses against several MERS-CoV strains, protecting NHPs from MERS-CoV challenge [27].

Other potential candidates have been suggested as MERS vaccines. For example, purified MERS-CoV full-length S nanoparticles in combination with appropriate adjuvants could elicit neutralizing antibodies in immunized mice [28]. Using reverse genetics, recombinant MERS-CoV may efficiently replicate in cell culture of human cell lines with broad tissue tropism, allowing an engineered mutant MERS-CoV lacking the structural E protein to be rescued and propagate in cells expressing the E protein in trans, thus providing a platform to develop live-attenuated, or recombinant, MERS-CoV-based vaccines [7,9].

3. Expert opinion

The induction of neutralizing antibodies is the key to the prevention of MERS-CoV infection, as supported by the fact that the reduction of lung pathogenesis and protection from MERS-CoV infection has been correlated with neutralizing antibody levels in the animal models [23,29]. In addition, vaccines that enjoy a high safety profile, combined with the ability to induce broad-spectrum immune responses and strong protective neutralizing antibodies, should have top priority for further development.

Efficacy and protective immunity of MERS candidate vaccines are, of necessity, evaluated in appropriate animal models. Thus, before moving to clinical trials, NHP rhesus macaque and common marmoset models [30,31] and camel...
Table 1. MERS vaccines under development.

| Vaccine name          | Vaccine type       | Viral antigen | Animal models                        | Status     | Ref. |
|-----------------------|--------------------|---------------|--------------------------------------|------------|-----|
| Ad5-S & Ad41-S        | Viral vector       | Full-length S | Mice                                 | Preclinical | [15]|
| Ad5.MERS-S/Ad5.MERS-S1| Viral vector       | Full-length S/S1 | Mice                                 | Preclinical | [14]|
| MVA-MERS-S            | Viral vector       | Full-length S | hDPP4-transduced mice                | Preclinical | [16]|
| S1 – 358 – 588-Fc     | Recombinant protein| S1-RBD (358 – 588) | Rabbits                             | Preclinical | [19]|
| MERS-CoV rRBD         | Recombinant protein| S1-RBD (367 – 606) | Mice                                | Preclinical | [41]|
| S-RBD-Fc              | Recombinant protein| S1-RBD (377 – 662) | Mice                                | Preclinical | [20]|
| S377 – 588-Fc         | Recombinant protein| S1-RBD (377 – 588) | Mice, rabbits, hDPP4-mice            | Preclinical | [21,23]|
| MERS                  | DNA                | Full-length S | Mice, camels, NHPs                  | Preclinical | [25]|
| S-DNA/S1 protein      | DNA + Recombinant protein | Full-length S/S1 | Mice, NHPs                         | Preclinical | [27]|
| MERS-S                | Nanoparticles      | Full-length S | Mice                                 | Preclinical | [28]|
| rMERS-CoVLR/MERS-CoV-ΔE| Recombinant virus | MERS-CoV      | Not tested                           | Cell culture | [7,9]|

MERS: Middle East respiratory syndrome; MERS-CoV: Middle East respiratory syndrome coronavirus; NHPs: Non-human primates.

model [32], have been established and utilized for such purposes. However, the use of NHP and camel models is financially and facility restrictive for many researchers. Fortunately, recent advancements in establishing small animal models, including Ad5/hDPP4-transduced mouse model [33] and hDPP4-transgenic mouse models [34], have provided a portable and economical platform for assessing the efficacy of MERS candidate vaccines, despite the fact that each of these animal models has its advantages and disadvantages.

Although very promising, the recombinant MERS-CoV-based vaccines will need to be further characterized in suitable MERS-CoV animal models to confirm their efficacy and safety. Viral vector-based vaccines, on the other hand, may show protective immunity in challenged mouse animals. However, these vaccines might have safety concerns by the presence of pre-existing immunity in humans (in the case of Ad) or the potential to induce harmful immune responses. Thus, safety tests are strongly recommended. Also, this vaccine type might lead to incomplete protection or fail to protect aged groups, as shown in the case of SARS-CoV vaccines [35]. By comparison, recombinant protein-based subunit vaccines possess the highest safety profile because they utilize full-length spike protein, or its subunit (e.g., S1) or fragment (e.g., RBD) as the antigen. In the presence of suitable adjuvants, this type of vaccine is generally able to induce higher titers of neutralizing antibody responses than those elicited by other vaccine types, and they can be easily injected via different pathways, including intramuscular injection, an adopted route for human vaccines. Importantly, some of these MERS subunit vaccines are shown to be protective against MERS-CoV infection in challenged mouse and/or NHP models [23,27], demonstrating their ability for further scale-up and/or human clinical trials.

Among these recombinant protein-based subunit vaccines, we believe that RBD-based vaccines are more effective and safer than those based on the full-length S protein. RBD contains the CND in the S protein, and most of the highly potent neutralizing antibodies target the RBD [21,36-38]. Recombinant proteins containing RBD induce strong neutralizing antibody responses and protection in the vaccinated animals against MERS-CoV infection [21,23]. In contrast, the full-length S protein contains some non-neutralizing immunodominant domains, which may compromise the immunogenicity with the CND in RBD, or even induces virus-enhancing or harmful immune responses, as demonstrated in the S protein of SARS-CoV [39]. This may be one of the reasons that the development of full-length S protein-based SARS vaccine has been discontinued. One may criticize that the vaccines based on the RBD sequences of the current MERS-CoV strains might be not effective against future emerged MERS-CoV strains with mutations in RBD. This should not be a problem for RBD-based vaccines because RBD contains several conformational neutralizing epitopes, and thus mutation(s) in one epitope may not significantly affect the neutralizing activity of antibodies elicited by other epitopes. For example, the RBD-specific mAb F11 could not neutralize the Bisha1 strain of MERS-CoV, whose RBD contains 509 mutation, but susceptible to neutralization of D12, another MERS-CoV RBD-specific mAb [27]. Previous studies have demonstrated that RBD of SARS-CoV Tor2 strain, which contains six different conformational neutralizing epitopes, induces antibodies in the vaccinated animals with neutralizing activity against all SARS-CoV strains tested, including those caused by the early SARS outbreaks (e.g., GD03 strain) and late SARS pandemics (e.g., Urbani strain), as well as the SARS-like CoV strain from civets (SZ strain) [40]. Although some epitopes outside MERS-CoV RBD may have neutralizing activity, such ability is significantly lower than that of the RBD. For example, neutralizing mAbs G2 and G4 target epitopes at MERS-CoV S1 and S2, respectively, both of which are outside the RBD, their neutralizing ability is not as potent as RBD-specific mAbs F11 and D12 [27]. Nevertheless, these non-RBD neutralizing epitopes, if being clearly identified, could be potentially included in vaccine design to increase the breadth and strength of MERS-CoV vaccines.

It is common knowledge that the process of vaccine approval is long and that it is further complicated by regulatory restrictions and a shortage of funds. As a case in point,
MERS vaccines are urgently needed, yet Big Pharma has consistently refused to invest funds for manufacturing or developing in pre-clinical and clinical studies based on the uncertainty of immediate return on such investments. In addition, adequate financial support from government entities is not guaranteed by the general lack of funds. As noted above, however, some firms in U.S. and DZIF Academy in Germany have taken the first step toward clinical trials of the two MERS vaccines based on DNA and viral vector, respectively. Big Pharma and governments of these countries and other parts of the world should take note of this signal and act accordingly.

**Declaration of interest**

The authors were funded by NIH grants R21AI109094, R21AI111152 and R01AI098775, as well as intramural funds from the New York Blood Center, grant NYB000348. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**Bibliography**

Papers of special note have been highlighted as either of interest (•) or of considerable interest (★★) to readers.

1. Zaki AM, Van BS, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20
2. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013;19(11):1819-23
3. Madani TA, Azhar EI, Hashem AM. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014;371(14):1360-1
4. WHO. Middle East Respiratory Syndrome coronavirus (MERS-CoV) - Saudi Arabia. Available from: http://www.who.int/csr/don/27-august-2015-mers-saudi-arabia/en/ [Last accessed 27 August 2015]
5. Oboho IK, Tomczyk SM, Al-Asmary AM, et al. 2014 MERS-CoV outbreak in Jeddah—link to health care facilities. N Engl J Med 2015;372(9):846-54
6. Maltezou HC, Tsiodras S. Middle East respiratory syndrome coronavirus: implications for health care facilities. Am J Infect Control 2014;42(12):1261-5
7. Almazan F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013;4(5):e00650-13
8. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012;2(3):264-75
9. Scooby T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2013;110(40):16157-62
10. Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 2015;89(4):1954-64
11. Raj VS, Mou H, Smith SL, et al. Dipetidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495(7440):251-4
12. This paper identified DPP4 as MERS-CoV’s receptor.
13. Muth D, Corman VM, Meyer B, et al. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol 2015;53(9):2951-5
14. Drosten C, Muth D, Corman VM, et al. An observational, laboratory-based study of outbreaks of Middle East Respiratory Syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015;60(3):369-77
15. Kim E, Okada K, Kenniston T, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014;32(45):5975-82
16. Volz A, Kupke A, Song F, et al. Protective efficacy of recombinant modified vaccinia virus ankara (MVA) delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 2015;89(16):8651-6
17. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013;87(21):11950-4
18. Paddock C. MERS vaccine ‘ready for human trials’. Medical News Today. Available from: http://www.medicalnewstoday.com/articles/296023.php [Last accessed 29 June 2015]
19. Mou H, Raj VS, van Kuppeveld FJ, et al. The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16):9379-83
20. Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013;87(17):9939-42
21. Ma C, Wang L, Tao X, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments – the importance of immunofocusing in subunit vaccine design. Vaccine 2014;32(46):6170-6
22. This paper demonstrating MERS-CoV RBD as an important vaccine target.
Middle East respiratory syndrome: current status and future prospects for vaccine development

binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014;32(18):2100-8

23. Zhang N, Channappanavar R, Ma C, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2015. doi: 10.1038/cmi.2015.03. [Epub ahead of print]

24. Tang J, Zhang N, Tao X, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 2015;11(5):1244-50

25. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015;7(301):301ra132

26. Inovio News Release. Inovio pharmaceuticals partners with geneone life science for MERS immunotherapy clinical development. Available from: http://ir.inovio.com/news/news-releases/news-releases-details/2015/Inovio-Pharmaceuticals-Partners-with-GeneOne-Life-Science-for-MERS-Immunotherapy-Clinical-Development/default.aspx [Last accessed 27 May 2015]

27. Wang L, Shi L, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015;6:7712

28. Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014;32(20):3169-74

29. Zhao J, Perera RA, Kayali G, et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 2015;89(11):6117-20

30. Falzarano D, de Wit E, Feldmann F, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 2014;10(8):e1004250

31. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013;110(41):16598-603

32. Adney DR, Van DN, Brown VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 2014;20(12):1999-2005

33. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014;111(13):4970-5

34. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of middle East respiratory syndrome coronavirus infection and disease. J Virol 2015;89(7):3659-70

35. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013;11(12):836-48

36. Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014;88(12):7045-53

37. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014;88(14):7796-805

38. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014;6(234):234ra59

39. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78(22):12672-6

40. He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006;176(10):6085-92

41. Lan J, Deng Y, Chen H, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 2014;9(11):e112602

Affiliation
Lanying Du1,2 & Shibo Jiang1,2
1,2*Authors for correspondence
1Lindsey F. Kimball Research Institute, New York Blood Center, NY, USA
Tel: +1 212 570 3459;
E-mail: ldu@nybloodcenter.org
2Fudan University, Shanghai Medical College and Institute of Medical Microbiology, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai, China
Tel: +1 212 570 3058;
E-mail: sjiang@nybloodcenter.org